


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6754960/publications.pdf Version: 2024-02-01



HENC CUI

#	Article	IF	CITATIONS
1	Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget, 2018, 9, 7522-7533.	0.8	41
2	Knockdown of long noncoding RNA CCDC144NL-AS1 attenuates migration and invasion phenotypes in endometrial stromal cells from endometriosisâ€. Biology of Reproduction, 2019, 100, 939-949.	1.2	31
3	Effects of Previous Laparoscopic Surgical Diagnosis of Endometriosis on Pregnancy Outcomes. Chinese Medical Journal, 2017, 130, 428-433.	0.9	26
4	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2436-2446.	0.8	24
5	Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people. Chinese Medical Journal, 2020, 133, 1285-1291.	0.9	13
6	Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. Journal of Obstetrics and Gynaecology, 2017, 37, 1065-1069.	0.4	12
7	Fibrinogen alpha chain is up-regulated and affects the pathogenesis of endometriosis. Reproductive BioMedicine Online, 2019, 39, 893-904.	1.1	12
8	Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 309-17.	0.7	12
9	Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival. Pathology Research and Practice, 2018, 214, 1115-1122.	1.0	11
10	Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. Journal of Ovarian Research, 2021, 14, 63.	1.3	11
11	Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer. Archives of Gynecology and Obstetrics, 2018, 297, 1235-1244.	0.8	10
12	IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 282-290.	0.7	9
13	Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Molecular Cancer Therapeutics, 2021, 20, 1735-1742.	1.9	8
14	Evaluation of Circulating Endometrial Cells as a Biomarker for Endometriosis. Chinese Medical Journal, 2017, 130, 2339-2345.	0.9	8
15	Tumor-derived exosomal circRNA051239 promotes proliferation and migration of epithelial ovarian cancer. American Journal of Translational Research (discontinued), 2021, 13, 1125-1139.	0.0	8
16	Shortening of the 3' untranslated region: an important mechanism leading to overexpression of HMGA2 in serous ovarian cancer. Chinese Medical Journal, 2014, 127, 494-9.	0.9	8
17	Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9. International Journal of Oncology, 2015, 47, 1405-1415.	1.4	7
18	Adenosine Triphosphate Regresses Endometrial Explants in a Rat Model of Endometriosis. Reproductive Sciences, 2016, 23, 924-930.	1.1	7

Heng Cui

#	Article	IF	CITATIONS
19	Preoperative low hematocrit is an adverse prognostic biomarker in ovarian cancer. Archives of Gynecology and Obstetrics, 2021, 303, 767-775.	0.8	7
20	Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 673-685.	0.7	7
21	Swyer's Syndrome with Mixed Ovarian Malignant Germ Cell Tumor and Ovarian Gonadoblastoma. Chinese Medical Journal, 2016, 129, 1752-1754.	0.9	7
22	Evaluation of a novel ovarian cancer-specific fluorescent antibody probe for targeted near-infrared fluorescence imaging. World Journal of Surgical Oncology, 2020, 18, 66.	0.8	6
23	Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 21303-10.	1.3	5
24	Nearâ€infrared dyeâ€labeled antibody COC183B2 enables detection of tiny metastatic ovarian cancer and optimizes fluorescenceâ€guided surgery. Journal of Surgical Oncology, 2020, 122, 1207-1217.	0.8	4
25	Production of transgenic mice expressing tumor virus A under ovarian-specific promoter 1 control using testis-mediated gene transfer. Molecular Medicine Reports, 2014, 9, 955-960.	1.1	3
26	Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. Frontiers in Immunology, 2021, 12, 707468.	2.2	3
27	Primary peritoneal serous carcinoma with signet ring cells. Gynecologic Oncology Case Reports, 2011, 1, 4-5.	0.9	2
28	Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models. BMC Cancer, 2018, 18, 81.	1.1	1
29	Successful pregnancy and childbirth in a patient with acute lymphoblastic leukaemia after busulfan-based myeloablative conditioning allogeneic haematopoietic stem cell transplantation: a case report. Journal of Obstetrics and Gynaecology, 2020, 40, 130-131.	0.4	1
30	Paraâ€∎ortic lymphadenectomy below inferior mesenteric artery versus renal vessels in stage <scp>IIIC</scp> epithelial ovarian cancer: A comparison of surgical outcomes. International Journal of Gynecology and Obstetrics, 2020, 148, 192-197.	1.0	0
31	Prediction of chemotherapeutic resistance in serous ovarian cancer with low-density custom microarray. Chinese Medical Journal, 2020, 133, 871-873.	0.9	Ο